首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   66篇
  免费   4篇
  国内免费   21篇
基础医学   6篇
临床医学   7篇
内科学   31篇
皮肤病学   1篇
特种医学   1篇
外科学   6篇
综合类   21篇
预防医学   2篇
药学   5篇
中国医学   10篇
肿瘤学   1篇
  2016年   3篇
  2015年   3篇
  2014年   2篇
  2013年   3篇
  2012年   3篇
  2011年   1篇
  2010年   6篇
  2009年   8篇
  2001年   1篇
  1999年   3篇
  1998年   1篇
  1996年   2篇
  1995年   1篇
  1994年   2篇
  1991年   1篇
  1988年   1篇
  1986年   3篇
  1982年   1篇
  1981年   2篇
  1980年   1篇
  1968年   1篇
  1965年   3篇
  1964年   2篇
  1963年   4篇
  1962年   4篇
  1960年   1篇
  1959年   2篇
  1958年   8篇
  1957年   7篇
  1956年   7篇
  1955年   1篇
  1933年   3篇
排序方式: 共有91条查询结果,搜索用时 15 毫秒
81.
82.
Aims:   The docetaxel and cyclophosphamide (TC) regimen is increasingly popular as adjuvant chemotherapy for operable breast cancers. We conducted a retrospective study in Hong Kong to evaluate the toxicity of this regimen in Chinese patients.
Methods:   Between January 2007 and May 2008 76 female Chinese patients with resected stage I–III operated invasive breast cancer were treated with 4 cycles of TC (75 and 600 mg/m2, respectively, administered i.v. every 3 weeks for four cycles) in two public regional cancer centers of Hong Kong. A total of 24 (32%) patients also received primary prophylactic ciprofloxacin (500 mg twice daily, day 5–14). Chemotherapy-related toxicities were graded by the CTCAE version 3.0.
Results:   The median age was 50 (range 26–67). A total of 68 (89%) patients successfully completed four cycles of chemotherapy. 72 (95%) and 16 (21%) patients developed grade 3–4 neutropenia and febrile neutropenia (FN) infection, respectively, in one or more cycles. However, no grade 3–4 anemia or thrombocytopenia events were observed. Other grade 3–4 non-hematological toxicities were also uncommon, apart from allergic reactions in two (3%) patients. No viral reactivation was observed among the 8 hepatitis B carriers. Patients with prophylactic ciprofloxacin had less grade 3–4 FN infection (13% vs 25%, P  = 0.214) and a higher chance of receiving the full scheduled dose (88% vs 62%, P  = 0.045) than patients without.
Conclusion:   The myelotoxicity of TC was substantially higher in Chinese patients compared with non-Chinese patients in developed countries. Routine prophylactic measures are recommended to maintain the dose levels and reduce the risk of FN.  相似文献   
83.
84.
85.
86.
87.
88.
89.
Pacemaker stimulation of the left ventricle is expected to yield a pattern of complete right bundle branch block, however, unusual patterns have been reported. The present report is a case of an unusual electrocardiographic pattern from left ventricular endocardial pacing in a patient with an atrial septal defect and acute myocarditis complicated by complete degree atrioventricular block.  相似文献   
90.
  • 1 Phenylephrine (1–100 γg/kg, intravenously) produced dose-dependent increases in heart rate and blood pressure in the pithed rat.
  • 2 The positive chronotropic response to phenylephrine (10 μg/kg) was reduced in a dose-dependent manner by propranolol (0.01–0.3 mg/kg), but higher doses of propranolol (up to 3 mg/kg) did not reduce the response by more than about 50%. The residual response was virtually abolished by phentolamine (0.3 mg/kg) or prazosin (3 μg/kg). Labetalol (3 mg/kg) which has both α- and β-blocking activity, also abolished the positive chronotropic response.
  • 3 The pressor response to phenylephrine (1–30 μg/kg) was enhanced by propranolol (1 mg/kg) and abolished by phentolamine (1 mg/kg) and prazosin (30 μg/kg). Labetalol (3 mg/kg) reduced the response to phenylephrine by 73%.
  • 4 Propranolol (0.3 mg/kg) completely blocked the chronotropic and vasodepressor effects of isoprenaline (0.1 μg/kg).
  • 5 It is concluded that phenylephrine acts on both α1- and β1-adrenoreceptors to produce an increase in heart rate, on α1-adrenoreceptors to produce vasoconstriction and on β2-adrenoreceptors to produce vasodilation. This latter effect is usually masked by the predominant vasoconstrictor action.
  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号